Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.16
MYL's Cash to Debt is ranked lower than
90% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. MYL: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.79 Max: 44.56
Current: 0.16
0.02
44.56
Equity to Asset 0.45
MYL's Equity to Asset is ranked lower than
75% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYL: 0.45 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.46 Max: 0.9
Current: 0.45
0.19
0.9
Interest Coverage 4.26
MYL's Interest Coverage is ranked lower than
77% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.86 vs. MYL: 4.26 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.61 Max: 9.19
Current: 4.26
0.83
9.19
F-Score: 5
Z-Score: 2.10
M-Score: -2.47
WACC vs ROIC
9.52%
7.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.43
MYL's Operating margin (%) is ranked higher than
69% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. MYL: 14.43 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s Operating margin (%) Range Over the Past 10 Years
Min: 5.8  Med: 16.36 Max: 26.53
Current: 14.43
5.8
26.53
Net-margin (%) 8.26
MYL's Net-margin (%) is ranked higher than
58% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.02 vs. MYL: 8.26 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s Net-margin (%) Range Over the Past 10 Years
Min: -3.53  Med: 9.01 Max: 14.68
Current: 8.26
-3.53
14.68
ROE (%) 8.30
MYL's ROE (%) is ranked higher than
55% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. MYL: 8.30 )
Ranked among companies with meaningful ROE (%) only.
MYL' s ROE (%) Range Over the Past 10 Years
Min: -14.72  Med: 14.57 Max: 29.99
Current: 8.3
-14.72
29.99
ROA (%) 3.62
MYL's ROA (%) is ranked higher than
50% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. MYL: 3.62 )
Ranked among companies with meaningful ROA (%) only.
MYL' s ROA (%) Range Over the Past 10 Years
Min: -2.47  Med: 4.61 Max: 9.21
Current: 3.62
-2.47
9.21
ROC (Joel Greenblatt) (%) 22.66
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.79 vs. MYL: 22.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.9  Med: 31.19 Max: 47.2
Current: 22.66
17.9
47.2
Revenue Growth (3Y)(%) 5.40
MYL's Revenue Growth (3Y)(%) is ranked higher than
50% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MYL: 5.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.1  Med: 15.20 Max: 54.5
Current: 5.4
-6.1
54.5
EBITDA Growth (3Y)(%) 5.20
MYL's EBITDA Growth (3Y)(%) is ranked lower than
55% of the 553 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. MYL: 5.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20.4  Med: 11.20 Max: 107.9
Current: 5.2
-20.4
107.9
EPS Growth (3Y)(%) 3.80
MYL's EPS Growth (3Y)(%) is ranked lower than
57% of the 509 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MYL: 3.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.1  Med: 3.80 Max: 110.4
Current: 3.8
-29.1
110.4
» MYL's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

MYL Guru Trades in Q2 2015

Larry Robbins 1,815,874 sh (New)
David Tepper 989,528 sh (New)
Louis Moore Bacon 210,000 sh (New)
Eric Mindich 1,456,404 sh (New)
Jim Simons 548,006 sh (New)
John Keeley 37,050 sh (New)
Kyle Bass 780,251 sh (New)
Steven Cohen 1,331,200 sh (+425.54%)
Mario Gabelli 33,250 sh (+232.50%)
John Paulson 21,913,061 sh (+46.59%)
George Soros 160,000 sh (unchged)
Tom Russo 5,850 sh (unchged)
Vanguard Health Care Fund 15,891,898 sh (unchged)
Joel Greenblatt Sold Out
First Eagle Investment Sold Out
Scott Black 185,573 sh (-1.06%)
Pioneer Investments 631,760 sh (-23.54%)
Paul Tudor Jones 12,766 sh (-88.34%)
» More
Q3 2015

MYL Guru Trades in Q3 2015

Jim Simons 1,716,741 sh (+213.27%)
Mario Gabelli 67,250 sh (+102.26%)
John Keeley 56,120 sh (+51.47%)
Vanguard Health Care Fund 23,262,875 sh (+46.38%)
Steven Cohen 1,000,000 sh (unchged)
Tom Russo 5,850 sh (unchged)
John Paulson 21,913,061 sh (unchged)
Eric Mindich Sold Out
Scott Black 180,575 sh (-2.69%)
Paul Tudor Jones 10,768 sh (-15.65%)
Pioneer Investments 365,302 sh (-42.18%)
Larry Robbins 934,006 sh (-48.56%)
David Tepper 470,071 sh (-52.50%)
Louis Moore Bacon 80,000 sh (-61.90%)
Steven Cohen 360,900 sh (-72.89%)
Kyle Bass 78,905 sh (-89.89%)
» More
Q4 2015

MYL Guru Trades in Q4 2015

David Einhorn 2,890,000 sh (New)
Joel Greenblatt 9,029 sh (New)
David Tepper 853,749 sh (+81.62%)
Pioneer Investments 469,785 sh (+28.60%)
Vanguard Health Care Fund 24,253,075 sh (+4.26%)
John Paulson 22,794,061 sh (+4.02%)
Tom Russo 5,850 sh (unchged)
Steven Cohen 1,000,000 sh (unchged)
Samuel Isaly 548,000 sh (unchged)
Kyle Bass Sold Out
Larry Robbins Sold Out
Jim Simons Sold Out
John Keeley 51,580 sh (-8.09%)
Paul Tudor Jones 8,100 sh (-24.78%)
Louis Moore Bacon 38,678 sh (-51.65%)
Mario Gabelli 26,450 sh (-60.67%)
Scott Black 48,980 sh (-72.88%)
Steven Cohen 100 sh (-99.97%)
» More
Q1 2016

MYL Guru Trades in Q1 2016

Joel Greenblatt 837,728 sh (+9178.19%)
Vanguard Health Care Fund 26,679,385 sh (+10.00%)
John Paulson 23,335,861 sh (+2.38%)
John Paulson 611,200 sh (unchged)
David Einhorn 2,890,000 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
John Keeley Sold Out
David Tepper Sold Out
Samuel Isaly Sold Out
Tom Russo 5,395 sh (-7.78%)
Scott Black 42,509 sh (-13.21%)
Paul Tudor Jones 6,455 sh (-20.31%)
Mario Gabelli 17,000 sh (-35.73%)
Pioneer Investments 54,144 sh (-88.47%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:ZTS, OTCPK:SGIOF, OTCPK:ESALY, NYSE:PRGO, OTCPK:MKGAY, OTCPK:TKPYY, OTCPK:APNHY, OTCPK:MTZPY, NYSE:RDY, OTCPK:TAISF, OTCPK:HKMPF, OTCPK:HLUYY, NYSE:VRX, OTCPK:MDABY, NYSE:MNK, NYSE:TARO, OTCPK:SFOSF, OTCPK:HYPMY, OTCPK:DNPUF, OTCPK:IPSEY » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Mylan NV together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Mylan NV was incorporated in Netherlands on July 7, 2014. The Company along with its subsidiaries is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. It also operates a research and development network that delivers a robust product pipeline. The Company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Specialty segment engages in the development and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and has also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.

Ratios

vs
industry
vs
history
P/E(ttm) 27.70
MYL's P/E(ttm) is ranked lower than
52% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.34 vs. MYL: 27.70 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s P/E(ttm) Range Over the Past 10 Years
Min: 7.05  Med: 25.31 Max: 112.56
Current: 27.7
7.05
112.56
Forward P/E 8.79
MYL's Forward P/E is ranked higher than
82% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.67 vs. MYL: 8.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.70
MYL's PE(NRI) is ranked lower than
52% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.24 vs. MYL: 27.70 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s PE(NRI) Range Over the Past 10 Years
Min: 7.05  Med: 25.72 Max: 200.11
Current: 27.7
7.05
200.11
Price/Owner Earnings (ttm) 35.82
MYL's Price/Owner Earnings (ttm) is ranked lower than
51% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.00 vs. MYL: 35.82 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MYL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.15  Med: 35.10 Max: 5766.67
Current: 35.82
13.15
5766.67
P/B 2.03
MYL's P/B is ranked higher than
61% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. MYL: 2.03 )
Ranked among companies with meaningful P/B only.
MYL' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.67 Max: 7.02
Current: 2.03
0.64
7.02
P/S 2.26
MYL's P/S is ranked higher than
55% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. MYL: 2.26 )
Ranked among companies with meaningful P/S only.
MYL' s P/S Range Over the Past 10 Years
Min: 0.39  Med: 1.81 Max: 4.71
Current: 2.26
0.39
4.71
PFCF 15.10
MYL's PFCF is ranked higher than
72% of the 189 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.95 vs. MYL: 15.10 )
Ranked among companies with meaningful PFCF only.
MYL' s PFCF Range Over the Past 10 Years
Min: 8.82  Med: 19.15 Max: 47.34
Current: 15.1
8.82
47.34
POCF 12.06
MYL's POCF is ranked higher than
69% of the 254 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.49 vs. MYL: 12.06 )
Ranked among companies with meaningful POCF only.
MYL' s POCF Range Over the Past 10 Years
Min: 5.86  Med: 12.42 Max: 40.9
Current: 12.06
5.86
40.9
EV-to-EBIT 23.49
MYL's EV-to-EBIT is ranked lower than
59% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. MYL: 23.49 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.3  Med: 17.90 Max: 36.9
Current: 23.49
-10.3
36.9
EV-to-EBITDA 11.97
MYL's EV-to-EBITDA is ranked higher than
66% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.28 vs. MYL: 11.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7  Med: 11.00 Max: 23.3
Current: 11.97
-17.7
23.3
PEG 3.72
MYL's PEG is ranked lower than
70% of the 291 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. MYL: 3.72 )
Ranked among companies with meaningful PEG only.
MYL' s PEG Range Over the Past 10 Years
Min: 0.71  Med: 2.73 Max: 11.5
Current: 3.72
0.71
11.5
Shiller P/E 75.37
MYL's Shiller P/E is ranked lower than
69% of the 149 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.12 vs. MYL: 75.37 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s Shiller P/E Range Over the Past 10 Years
Min: 14.33  Med: 68.45 Max: 152.12
Current: 75.37
14.33
152.12
Current Ratio 1.67
MYL's Current Ratio is ranked lower than
67% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MYL: 1.67 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 3.12 Max: 8.49
Current: 1.67
1.21
8.49
Quick Ratio 1.13
MYL's Quick Ratio is ranked lower than
71% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. MYL: 1.13 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.58 Max: 6.76
Current: 1.13
0.85
6.76
Days Inventory 132.22
MYL's Days Inventory is ranked lower than
61% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.06 vs. MYL: 132.22 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 136.05 Max: 168.24
Current: 132.22
88.95
168.24
Days Sales Outstanding 96.87
MYL's Days Sales Outstanding is ranked lower than
66% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.75 vs. MYL: 96.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.32  Med: 84.21 Max: 107.26
Current: 96.87
70.32
107.26
Days Payable 72.00
MYL's Days Payable is ranked higher than
51% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.79 vs. MYL: 72.00 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 44.56  Med: 72.50 Max: 101.21
Current: 72
44.56
101.21

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.31
MYL's Price/Projected FCF is ranked higher than
75% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. MYL: 1.31 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.41 Max: 2.5
Current: 1.31
0.62
2.5
Price/DCF (Earnings Based) 2.59
MYL's Price/DCF (Earnings Based) is ranked lower than
84% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. MYL: 2.59 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.25
MYL's Price/Median PS Value is ranked lower than
61% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. MYL: 1.25 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 1.87 Max: 3.43
Current: 1.25
0.36
3.43
Price/Peter Lynch Fair Value 3.08
MYL's Price/Peter Lynch Fair Value is ranked lower than
83% of the 172 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.44 vs. MYL: 3.08 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.67  Med: 1.93 Max: 10.2
Current: 3.08
0.67
10.2
Earnings Yield (Greenblatt) (%) 4.24
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
58% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYL: 4.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.7  Med: 5.30 Max: 19
Current: 4.24
2.7
19
Forward Rate of Return (Yacktman) (%) 13.13
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 326 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.89 vs. MYL: 13.13 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.7  Med: 14.80 Max: 28.4
Current: 13.13
7.7
28.4

More Statistics

Revenue (TTM) (Mil) $9,749
EPS (TTM) $ 1.56
Beta1.30
Short Percentage of Float5.95%
52-Week Range $37.59 - 73.91
Shares Outstanding (Mil)508.34

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 10,940 12,828 13,560
EPS ($) 4.84 5.61 6.37
EPS w/o NRI ($) 4.84 5.61 6.37
EPS Growth Rate
(3Y to 5Y Estimate)
7.26%
» More Articles for NAS:MYL

Headlines

Articles On GuruFocus.com
Growing Generic Drug Market a Good Opportuity for 2 India Firms May 30 2016 
Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
John Keeley Comments on Mylan Labs Apr 26 2016 
Ackman to Testify About Valeant Before Senate Apr 26 2016 
Mawer's Investment Newsletter 1st Quarter Apr 15 2016 
Insiders Keep on Selling Facebook and Ford Apr 08 2016 
Buy Perrigo After a Big Selloff? Yes Apr 04 2016 
David Einhorn's Top 5 New Q4 Buys Feb 16 2016 
David Einhorn Rebounds – Somewhat Feb 09 2016 
Keeley Funds Comments on Mylan N.V. Feb 03 2016 

More From Other Websites
EU mergers and takeovers (June 30) Jun 30 2016
What New Medicines Were Recommended during the CHMP’s June Meeting? Jun 28 2016
Inside the CHMP’s June Meeting and Outcome Jun 28 2016
Mylan’s Key Developments and Big Plans: What You Should Know Jun 28 2016
Mylan CEO Bresch on Brexit Exposure, Regulation Jun 28 2016
Mylan CEO Bresch on Brexit Exposure, Regulation Jun 28 2016
Mylan’s Profits: Can You Expect Changes? Jun 28 2016
Mylan Launches Generic Version of Glaxo's Avodart in U.S. Jun 27 2016
Why Mylan’s Specialty Segment Reported Strong Q1 Growth Jun 27 2016
Mylan NV breached its 50 day moving average in a Bearish Manner : MYL-US : June 27, 2016 Jun 27 2016
Mylan’s Generics Segment: 1Q16 Must-Knows Jun 27 2016
MYLAN N.V. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 24 2016
Mylan Unveils Generic Avodart Capsules Jun 24 2016
What’s the Story behind Mylan’s Revenue Growth? Jun 24 2016
Why Is Mylan’s Valuation so Low? Our Diagnosis Jun 24 2016
Mylan Launches Generic Avodart® Capsules Jun 24 2016
J.P. Morgan Very Positive on 3 Battered Specialty Pharmaceutical Stocks Jun 24 2016
Mylan Donates €1 Million to the Princess Máxima Center for Pediatric Oncology Jun 23 2016
Valeant Pharmaceuticals: Now You Downgrade It? Jun 23 2016
Mylan Says Indian Drug Industry Needs More Transparency From FDA Jun 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)